64 results
20-F/A
2023 FY
CYTO
Altamira Therapeutics Ltd
22 Apr 24
Annual report (foreign) (amended)
4:31pm
1,256,493 (2022: CHF 1,172,818).
For the year ended December 31, 2023, the amount set aside or accrued by us to provide pension, retirement or similar … in such pass through entities;
tax-exempt entities, including an “individual retirement account” or “Roth IRA”;
persons that own or are deemed to own
424B5
CYTO
Altamira Therapeutics Ltd
19 Jan 24
Prospectus supplement for primary offering
4:40pm
an “individual retirement account” or “Roth IRA”;
persons that own or are deemed to own ten percent or more of the vote or value of our shares;
persons who
424B4
CYTO
Altamira Therapeutics Ltd
7 Jul 23
Prospectus supplement with pricing info
4:14pm
in such pass-through entities;
tax-exempt entities, including an “individual retirement account” or “Roth IRA”;
persons that own or are deemed to own
F-1/A
5wyge
3 Jul 23
Registration statement (foreign) (amended)
7:09pm
F-1
3t9pw1uws egyws6m
16 Jun 23
Registration statement (foreign)
5:01pm
6-K
EX-10.1
u8rk h2lsifu2lqj0r5o
5 Dec 22
Report of Foreign Private Issuer
4:30pm
424B5
cnhgo1z5r9ml90 flga
15 Jan 21
Prospectus supplement for primary offering
4:32pm
424B5
dp6bz8koulx
3 Dec 20
Prospectus supplement for primary offering
5:25pm
6-K
EX-10.1
7fe c9bmz
23 Apr 20
Report of Foreign Private Issuer
4:38pm
S-8
EX-99.1
ldqrb33phfvxkk2q5
19 Jul 19
Registration of securities for employees
4:32pm
6-K
EX-4.4
sncal27y4e7sj3k
16 May 19
Report of Foreign Private Issuer
7:26am
6-K
EX-1.1
t0qfrd0xc
16 May 19
Report of Foreign Private Issuer
7:26am
6-K
EX-4.3
n6pbyezm
16 May 19
Report of Foreign Private Issuer
7:26am
424B4
owk5b616
14 May 19
Prospectus supplement with pricing info
4:06pm